Modifiable risk factors for asthma exacerbations during the COVID-19 pandemic: a population-based repeated cross-sectional study using the Research and Surveillance Centre primary care database.

Asthma COVID-19 Cluster analysis Exacerbations Prevalence Risk factors

Journal

The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 20 11 2023
revised: 03 05 2024
accepted: 03 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

There were substantial reductions in asthma exacerbations during the COVID-19 pandemic for reasons that remain poorly understood. We investigated changes in modifiable risk factors which might help explain the reductions in asthma exacerbations. Multilevel generalised linear mixed models were fitted to examine changes in modifiable risk factors for asthma exacerbations during 2020-2022, compared to pre-pandemic year (2019), using observational, routine data from general practices in the Oxford-Royal College of General Practitioners Research and Surveillance Centre. Asthma exacerbations were defined as any of GP recorded: asthma exacerbations, prescriptions of prednisolone, accident and emergency department attendance or hospitalisation for asthma. Modifiable risk factors of interest were ownership of asthma self-management plan, asthma annual review, inhaled-corticosteroid (ICS) prescriptions, influenza vaccinations and respiratory-tract-infections (RTI). Compared with 2019 (n = 550,995), in 2020 (n = 565,956) and 2022 (n = 562,167) (p < 0.05): asthma exacerbations declined from 67.1% to 51.9% and 61.1%, the proportion of people who had: asthma exacerbations reduced from 20.4% to 15.1% and 18.5%, asthma self-management plans increased from 28.6% to 37.7% and 55.9%; ICS prescriptions increased from 69.9% to 72.0% and 71.1%; influenza vaccinations increased from 14.2% to 25.4% and 55.3%; current smoking declined from 15.0% to 14.5% and 14.7%; lower-RTI declined from 10.5% to 5.3% and 8.1%; upper-RTI reduced from 10.7% to 5.8% and 7.6%. There was cluster effect of GP practices on asthma exacerbations (p = 0.001). People with asthma were more likely (p < 0.05) to have exacerbations if they had LRTI (seven times(x)), had URTI and ILI (both twice), were current smokers (1.4x), PPV vaccinated (1.3x), seasonal flu vaccinated (1.01x), took ICS (1.3x), had asthma reviews (1.09x). People with asthma were less likely to have exacerbations if they had self-management plan (7%), and were partially (4%) than fully COVID-19 vaccinated. We have identified changes in modifiable risk factors for asthma exacerbation that need to be maintained in the post-pandemic era. Asthma UK Centre for Applied Research and Health Data Research UK.

Sections du résumé

Background UNASSIGNED
There were substantial reductions in asthma exacerbations during the COVID-19 pandemic for reasons that remain poorly understood. We investigated changes in modifiable risk factors which might help explain the reductions in asthma exacerbations.
Methods UNASSIGNED
Multilevel generalised linear mixed models were fitted to examine changes in modifiable risk factors for asthma exacerbations during 2020-2022, compared to pre-pandemic year (2019), using observational, routine data from general practices in the Oxford-Royal College of General Practitioners Research and Surveillance Centre. Asthma exacerbations were defined as any of GP recorded: asthma exacerbations, prescriptions of prednisolone, accident and emergency department attendance or hospitalisation for asthma. Modifiable risk factors of interest were ownership of asthma self-management plan, asthma annual review, inhaled-corticosteroid (ICS) prescriptions, influenza vaccinations and respiratory-tract-infections (RTI).
Findings UNASSIGNED
Compared with 2019 (n = 550,995), in 2020 (n = 565,956) and 2022 (n = 562,167) (p < 0.05): asthma exacerbations declined from 67.1% to 51.9% and 61.1%, the proportion of people who had: asthma exacerbations reduced from 20.4% to 15.1% and 18.5%, asthma self-management plans increased from 28.6% to 37.7% and 55.9%; ICS prescriptions increased from 69.9% to 72.0% and 71.1%; influenza vaccinations increased from 14.2% to 25.4% and 55.3%; current smoking declined from 15.0% to 14.5% and 14.7%; lower-RTI declined from 10.5% to 5.3% and 8.1%; upper-RTI reduced from 10.7% to 5.8% and 7.6%. There was cluster effect of GP practices on asthma exacerbations (p = 0.001). People with asthma were more likely (p < 0.05) to have exacerbations if they had LRTI (seven times(x)), had URTI and ILI (both twice), were current smokers (1.4x), PPV vaccinated (1.3x), seasonal flu vaccinated (1.01x), took ICS (1.3x), had asthma reviews (1.09x). People with asthma were less likely to have exacerbations if they had self-management plan (7%), and were partially (4%) than fully COVID-19 vaccinated.
Interpretation UNASSIGNED
We have identified changes in modifiable risk factors for asthma exacerbation that need to be maintained in the post-pandemic era.
Funding UNASSIGNED
Asthma UK Centre for Applied Research and Health Data Research UK.

Identifiants

pubmed: 38846423
doi: 10.1016/j.lanepe.2024.100938
pii: S2666-7762(24)00105-4
pmc: PMC11153226
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100938

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

AS was a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group and Astra-Zeneca's COVID-19 Thrombotic Thrombocytopenic Advisory Group and is a member of the Scottish Government's Standing Committee on Pandemic Preparedness; all roles are unremunerated. SdeL is the director of Royal College of GPs Research and Surveillance Centre (RSC) the primary care sentinel network, UK Health Security Agency funded. SdeL has had research funded by AstraZeneca, Moderna, GSK, Sanofi and Seqirus, has spoken at Seqirus and Roche funded events, was a member of advisory boards for AstraZeneca, Sanofi and Seqirus and had AstraZeneca funded attendance at a European conference, all fees for these events were paid to the University of Oxford.

Auteurs

Mome Mukherjee (M)

Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.
HDR UK Better Care, The University of Edinburgh, Edinburgh, UK.
HDR UK BREATHE Data Hub, The University of Edinburgh, Edinburgh, UK.
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

Cecilia Okusi (C)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

Gavin Jamie (G)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

Rachel Byford (R)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

Filipa Ferreira (F)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

Utkarsh Agarwal (U)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

David Weatherill (D)

Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.

Monica Fletcher (M)

Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.
HDR UK BREATHE Data Hub, The University of Edinburgh, Edinburgh, UK.

Jennifer K Quint (JK)

HDR UK BREATHE Data Hub, The University of Edinburgh, Edinburgh, UK.
School of Public Health & National Heart and Lung Institute, Imperial College London, London, UK.

Mohammad Romel Bhuia (M)

Department of Statistics, Shahjalal University of Science and Technology (SUST), Sylhet, 3114, Bangladesh.

Simon de Lusignan (S)

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.
Royal College of General Practitioners (RCGP), 30 Euston Square, London, NW1 2FB, UK.

Sir Aziz Sheikh (SA)

Asthma UK Centre for Applied Research, Usher Institute, The University of Edinburgh, Edinburgh, UK.
HDR UK Better Care, The University of Edinburgh, Edinburgh, UK.
HDR UK BREATHE Data Hub, The University of Edinburgh, Edinburgh, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Eagle House, Walton Well Rd, Oxford, OX2 6ED, UK.

Classifications MeSH